![Figure 10 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink Figure 10 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink](https://media.springernature.com/full/springer-static/image/art%3A10.1007%2Fs12325-016-0345-2/MediaObjects/12325_2016_345_Fig10_HTML.gif)
Figure 10 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink
![Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders - Abdel‐Aziz - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders - Abdel‐Aziz - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/56b54893-a755-443e-8799-cf5cdc07ca10/apt16295-fig-0001-m.jpg)
Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders - Abdel‐Aziz - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
![Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020 (NASDAQ:PHAT) | Seeking Alpha Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020 (NASDAQ:PHAT) | Seeking Alpha](https://static.seekingalpha.com/uploads/2020/2/18/24288543-15820442182806556_origin.png)
Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020 (NASDAQ:PHAT) | Seeking Alpha
![Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders - Abdel‐Aziz - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders - Abdel‐Aziz - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b87bd999-2a82-4753-9b40-c44780b649de/apt16295-toc-0001-m.jpg)
Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders - Abdel‐Aziz - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
![JCM | Free Full-Text | Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options | HTML JCM | Free Full-Text | Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options | HTML](https://www.mdpi.com/jcm/jcm-08-00179/article_deploy/html/images/jcm-08-00179-g001.png)
JCM | Free Full-Text | Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options | HTML
![Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases - ScienceDirect Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0163725816301437-gr1.jpg)
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases - ScienceDirect
![Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes - Journal of Pharmaceutical Sciences Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes - Journal of Pharmaceutical Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/803249c3-ebfe-4e27-87f4-52842b5ce21a/gr2.jpg)
Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes - Journal of Pharmaceutical Sciences
![Figure 1 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink Figure 1 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink](https://media.springernature.com/full/springer-static/image/art%3A10.1007%2Fs12325-016-0345-2/MediaObjects/12325_2016_345_Fig1_HTML.gif)
Figure 1 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink
![Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020 (NASDAQ:PHAT) | Seeking Alpha Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020 (NASDAQ:PHAT) | Seeking Alpha](https://static.seekingalpha.com/uploads/2020/2/18/24288543-15820442333958082_origin.png)
Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020 (NASDAQ:PHAT) | Seeking Alpha
![Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility | Journal of Pharmacology and Experimental Therapeutics Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/sites/default/files/highwire/jpet/364/2.cover-source.jpg)
Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility | Journal of Pharmacology and Experimental Therapeutics
![Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. - Abstract - Europe PMC Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6034668/bin/jnm-24-334f2.jpg)
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. - Abstract - Europe PMC
![PDF) Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease? PDF) Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?](https://www.researchgate.net/profile/Carmelo-Scarpignato/publication/283323212/figure/fig1/AS:290271486070787@1446217523177/Role-of-K-in-the-H-K-ATPase-functioning-and-potassium-competitive-interaction-of_Q320.jpg)
PDF) Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
![Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action - ScienceDirect Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0968089617304972-fx1.jpg)
Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action - ScienceDirect
![Figure 2 from Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | Semantic Scholar Figure 2 from Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/48592401bc566ff67bac885d8850c10294850ad9/4-Figure2-1.png)
Figure 2 from Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | Semantic Scholar
![Vonoprazan-based therapy for <i>Helicobacter pylori</i> eradication: experience and clinical evidence. - Abstract - Europe PMC Vonoprazan-based therapy for <i>Helicobacter pylori</i> eradication: experience and clinical evidence. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5076777/bin/10.1177_1756283X16668093-fig1.jpg)
Vonoprazan-based therapy for <i>Helicobacter pylori</i> eradication: experience and clinical evidence. - Abstract - Europe PMC
![Simplified schematic description: differences between 'conventional'... | Download Scientific Diagram Simplified schematic description: differences between 'conventional'... | Download Scientific Diagram](https://www.researchgate.net/profile/Yuko-Akazawa/publication/308574248/figure/fig1/AS:560710826823680@1510695286902/Simplified-schematic-description-differences-between-conventional-proton-pump.png)